Pharmaceutical use of a composition including a carbonaceous material and an active particle

Patent metadata

Field	Value
Publication number	US-9358254-B2
Application number	US-201314041666-A
Country	US
Kind code	B2
Filing date	Sep 30, 2013
Priority date	Jun 5, 2013
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

A method of treating or preventing Helicobacter pylori infection in a subject, includes the step of orally administering to the subject a composition including a carbonaceous material that has a pore defined therein which has a radius of more than 0 nm but less than 2.5 nm; and from 0.001-15% by weight, based on weight of the carbonaceous material, of an active particle coated that is on the carbonaceous material and that is made of a material selected from the group consisting of silver, gold, aluminum, zinc, copper, and titanium dioxide.

First claim

What is claimed is:

1. A method of treating or preventing Helicobacter pylori infection in a subject, comprising the step of:
orally administering to the subject a composition that is ingestible by the subject with substantially no side effects and consists of:
a carbonaceous material that has pores defined therein, each pore of which has a radius of more than 0 nm but less than 2.5 nm, and that is effective to absorb Helicobacter pylori ; and
from 0.001-15% by weight, based on weight of the carbonaceous material, of active particles that are coated on the carbonaceous material, that are effective to kill Helicobacter pylori , and that are made of a material selected from the group consisting of silver, gold, aluminum, zinc, copper, and titanium dioxide.

2. The method as claimed in claim 1 , wherein the carbonaceous material is selected from the group consisting of an activated carbon fiber, an activated carbon powder, a charcoal material, a bamboo charcoal granule, a carbon black, a graphite powder, a swelling graphite powder, and a carbon powder made from phenol formaldehyde resins or artificial resins.

3. The method as claimed in claim 2 , wherein the carbonaceous material is an activated carbon fiber.

4. The method as claimed in claim 1 , wherein the carbonaceous material has a surface area of 400-2,500 m 2 /g.

5. The method as claimed in claim 1 , wherein the active particles have a particle diameter of 1 nm-500 μm.

6. The method as claimed in claim 1 , wherein the active particles have a leachability from the carbonaceous material in vivo that is less than that which could cause damage to the subject.

7. The method as claimed in claim 1 , wherein the composition has a form of a capsule, a tablet, or a powder, or is included in a suspension or an emulsifier.

8. The method as claimed in claim 1 , wherein the composition is included in a health food or a health drink.

9. The method as claimed in claim 1 , wherein the method treats a gastric disease caused by a Helicobacter pylori infection in the subject, and wherein the disease is selected from the group consisting of enterogastritis, gastric ulcers, and duodenal ulcers.

10. The method as claimed in claim 1 , wherein the composition is ingestible by the subject with no side effects.

11. The method as claimed in claim 3 , wherein the carbonaceous material has a length of more than 0 mm and less than 0.1 mm, and a diameter of more than 0 μm and less than 10 μm.

12. The method as claimed in claim 3 , wherein the material of the active particles is silver.

13. The method as claimed in claim 12 , wherein the carbonaceous material has a length of more than 0 mm and less than 0.1 mm, and a diameter of more than 0 μm and less than 10 μm.

14. The method as claimed in claim 12 , wherein the active particles have a particle diameter of 1 nm-500 μm.

15. The method as claimed in claim 12 , wherein the active particles have a leachability from the carbonaceous material in vivo that is less than that which could cause damage to the subject.

16. The method as claimed in claim 12 , wherein the composition has a form of a capsule, a tablet, or a powder, or is included in a suspension or an emulsifier.

17. The method as claimed in claim 12 , wherein the composition is included in a health food or a health drink.

18. The method as claimed in claim 12 , wherein the method treats a gastric disease caused by a Helicobacter pylori infection in the subject, and wherein the disease is selected from the group consisting of enterogastritis, gastric ulcers, and duodenal ulcers.

Assignees

• Univ Feng Chia

Inventors

• Ko Tse-Hao

Classifications

• A61P31/02

  Local antiseptics · CPC title

• A61K33/38 Primary

  Silver; Compounds thereof · CPC title

• A61K33/06

  Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay} · CPC title

• A61P1/14

  Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents · CPC title

• A61K33/44

  Elemental carbon, e.g. charcoal, carbon black · CPC title